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Oral Presentations S1830%; MUD, Grade I-II: 20%, Grade III-IV: 20%. CIN of chronic
GVHD was: MSD, limited: 11%, extensive: 0%; MUD, limited:
0%, extensive: 0%. Acute GVHDwas treated to resolution with ste-
roid and ongoing CSA therapy, and all patients weaned from immu-
nosuppression by 1 year. There was no significant difference in
regimen-related morbidity or mortality between MSD and MUD
HCT using this risk-adapted modification of conditioning for
MUD HCT. Though in a limited number of patients, our results
suggest that immunomodulatory TLI/CTX/rATG conditioning is
a promising option for MUD HCT in SAA patients. We propose
to examine this in a prospective clinical trial using CTX/rATG for
MSD HCT versus TLI/CTX/rATG for MUD HCT within 3
months of diagnosis for pediatric and young adult patients with idi-
opathic SAA.79
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Recently published reports indicate that the outcome of unrelated
donor hematopoietic stem cell transplantation (HSCT) in patients
with leukemia is comparablewith thatof transplantation from identical
family donors.Wewould like toprove that the outcomesof related and
unrelated transplantation are favorably comparable inchildrenwith se-
vere thalassemia. We reviewed transplant outcome in 87 consecutive
children with severe thalassemia who underwent allogeneic HSCT
the related-donor stem cells (n 5 57) or unrelated-donor stem cells
(n5 30) between September 1992 and July 2010. Analysis of engraft-
ment, frequency of procedure related complications, and thalassemia-
free survival revealed no advantage from use of related-donor stem
cells. The thalassemia-free survival estimate for recipients of related-
donor stem cells was 86% compared with 75% in the unrelated-donor
stemcells group (p50.09).Thepresent studyprovides andevidence to
support the view that it is therefore quite reasonable to consider unre-
lated HSCT as an acceptable therapeutic approach in severe thalasse-
mia, at least for patients who are not fully compliant with conventional
treatment anddonot yet show irreversible severe complications of iron
overload. Moreover, we also have proved that our new reduced inten-
sity conditioning regimen approach can overcome the past poor result
ofHSCT in class 3 lucarelli thalassemia (age$ 10 years) patients (n5
16). Both of the thalassemia free survival and overall survival rates in
this group are 88%.Finally,we have studied the cost utility analysis be-
tweenHSCTandhypertransfusionwith iron chelation therapy in thal-
assemia patients. We can prove that matched related donor
transplantation in thalassemia patients appears to be a cost effective
and affordable treatment for thalassemia patients younger than 10
years of age.80
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Clinical outcomes for children admitted to the pediatric intensive
care unit (PICU) are improving with advances in supportive care
strategies. We have reviewed outcomes of children admitted to
PICU after hematopoetic stem cell transplantation (HSCT) to de-
termine the likely outcome for this challenging group of patients.
A retrospective review of our PICU and HSCT databases was per-
formed from July 2004 through June 2009. Over this period, 136
HSCT recipients accounted for 260 PICU admissions. Eighty seven
percent of patients (118/136) had allogeneic HSCT and 13% (17/
136) autologous HSCT. Patients admitted to PICU were atincreased risk of subsequent PICU admission, with an average of 2
PICU admissions per patient. Sixty six percent of transplants (90/
136) were myeloablative, 32% (43/136) were reduced intensity and
2% (2/136) were without conditioning regimen (SCID patients).
Eighty six percent of all allogeneic HSCT (102/118) were from un-
related donors. Eighty two percent of admitted patients (213/260)
survived to PICU discharge. Forty three percent of patients are cur-
rently surviving with a median follow up of 2.9 years (1.1-6.1 yrs).
The median PRISM II score for this cohort was 8 (0-47) days, and
median length of stay was 4 days (1-172 days). Thirty nine percent
of admitted (100/260) required intubation and mechanical ventila-
tion and 58% survived to be discharged from the PICU. Forty two
percent of admitted (109/260) required inotropes or vasopressor
support and 66% of these cases survived to PICU discharge. Four-
teen percent of admitted (36/260) required renal replacement ther-
apy and 50% survived to PICU discharge. The LOS, PRISM II
score, and ventilator days were all significantly lower for patients
who survived to PICUdischarge compared to patients who died dur-
ing their PICU admission [LOS (median 3 vs. 13 days, p\ 0.001),
PRISM II score (median 7 vs. 13, p\0.001), ventilator days (median
5 vs. 12 days, p\ 0.002)]. In summary, we report 82% survival to
PICU discharge, with overall 43% survival at a median follow-up
of nearly 3 years for all HSCT patients admitted to our PICU.
Our data suggest improved survival outcomes for this high risk pa-
tient population compared to historical values.81
BLOOD AND NOT URINE BK VIRAL LOAD PREDICTS OUTCOME IN CHIL-
DREN WITH HEMORRHAGIC CYSTITIS AND VIREMIA AFTER STEM CELL
TRANSPLANTATION
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BK virus is a significant cause of hemorrhagic cystitis after stem
cell transplantation (SCT), however, its role in nephropathy post-
SCT is not well studied. We retrospectively evaluated 314 consecu-
tive SCT patients treated at our institution since 2007, when BK
PCR first became clinically available. BK studies were performed
for hematuria or cystitis, not as routine viral screening. Thirty five
SCT patients (11%) had documented hemorrhagic cystitis. Urine
for BK virus was tested in 33/35 patients and was positive in 30
(91%). Average maximum urine viral load was 8 billion copies/
ml, and 73% of patients had a maximum urine viral load . 1 billion
copies/ml. Sixty percent (21/35) of patients with hemorrhagic cystitis
had plasma BK virus tested, and all of them had viremia (n 5 21,
100%). Patients with a maximum plasma viral load of. 10,000 cop-
ies/ml (high viremia; n 5 10) had worse renal outcome and greater
mortality attributed to BK virus compared to patients with #
10,000 copies/ml (low viremia; n 5 11) (table). Specifically, patients
with high viremia had significantly higher creatinine elevation from
pre-SCT baseline. Sixty percent of patients with high plasma viral
load required renal replacement therapy, and half of them developed
end stage renal disease despite BK therapy. Three patients with high
viremia had renal biopsies diagnostic for polyoma virus-associated
nephropathy. Hemorrhagic cystitis was also more severe in the
high viremia group, with half of patients requiring surgical interven-
tions and bladder irrigations for obstructive uropathy. Conversely,
the majority of patients with low viremia had transient elevations
in creatinine and hemorrhagic cystitis that resolved over time. In
summary, BK viremia. 10,000 copies/ml was associated with signif-
icant nephropathy and severe hemorrhagic cystitis following SCT in
our patient cohort. Although majority of SCT patients with hemor-
rhagic cystitis had very high urine viral load, only patients with high
viremia developed nephropathy, end stage renal disease and died
from this infection. Therefore, the degree of viremia, but not viruria,
may identify patients at risk who would benefit from early or aggres-
sive therapy. Future studies should determine optimal monitoring
and treatment protocols for these patients.
